Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07354074 · ClinicalTrials.gov registry record · Phase 2
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT07354074 is a Phase 2 study that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT07354074, a Phase 2 study, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.
Interventions
- DRUG Asciminib single agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-04-28 |
| Est. Completion | 2033-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07354074
The ClinicalTrials.gov registry entry for NCT07354074 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Asciminib single agent is the first listed.
NCT07354074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07354074 about?
NCT07354074 is a clinical study titled "Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP". The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resist...
What is the current status of trial NCT07354074?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2026-04-28. Estimated completion is 2033-02-23.
What interventions are being tested in trial NCT07354074?
The interventions under investigation include: Asciminib single agent (DRUG).
Who is sponsoring clinical trial NCT07354074?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.